Univariate analysis of risk factors for cardiovascular events in SLE patients
| . | HR (95% CI) . | P . |
|---|---|---|
| Age (for 10-year aged) | 1.79 (1.37, 2.34) | <0.0001 |
| Female gender | 0.81 (0.25, 2.69) | 0.7336 |
| Smoker, current | 1.96 (0.91, 4.22) | 0.0859 |
| Diabetes | 1.20 (0.16, 8.85) | 0.8588 |
| Dyslipidaemia | 4.88 (2.44, 9.76) | <0.0001 |
| Hypertension | 2.89 (1.39, 6.01) | 0.0045 |
| BMI | 1.05 (0.99, 1.12) | 0.1277 |
| BMI >30 kg/m2 | 1.71 (0.65, 4.51) | 0.2745 |
| Duration of SLE disease | 1.06 (1.02, 1.10) | 0.0024 |
| Lupus nephritis | 0.68 (0.16, 2.88) | 0.5983 |
| aPL antibodies | 1.48 (0.71, 3.10) | 0.2985 |
| APS | 1.93 (0.85, 4.36) | 0.1159 |
| SLEDAI | 1.01 (0.87, 1.18) | 0.8758 |
| SLEDAI score >4 | 1.31 (0.45, 3.78) | 0.6155 |
| Low C3 | 0.50 (0.15, 1.64) | 0.251 |
| Hormonal contraception | 0 (0-Inf) | 0.9976 |
| Steroids | 1.95 (0.46, 8.22) | 0.3614 |
| Immunosuppressive drugsa | 1.63 (0.75, 3.53) | 0.2153 |
| Biological therapyb | 1.69 (0.59, 4.87) | 0.3274 |
| HCQ, ng/ml | 1.00 (0.99, 1.00) | 0.6526 |
| HS-cTnT, ng/l | 1.01 (1.00, 1.02) | 0.0066 |
| . | HR (95% CI) . | P . |
|---|---|---|
| Age (for 10-year aged) | 1.79 (1.37, 2.34) | <0.0001 |
| Female gender | 0.81 (0.25, 2.69) | 0.7336 |
| Smoker, current | 1.96 (0.91, 4.22) | 0.0859 |
| Diabetes | 1.20 (0.16, 8.85) | 0.8588 |
| Dyslipidaemia | 4.88 (2.44, 9.76) | <0.0001 |
| Hypertension | 2.89 (1.39, 6.01) | 0.0045 |
| BMI | 1.05 (0.99, 1.12) | 0.1277 |
| BMI >30 kg/m2 | 1.71 (0.65, 4.51) | 0.2745 |
| Duration of SLE disease | 1.06 (1.02, 1.10) | 0.0024 |
| Lupus nephritis | 0.68 (0.16, 2.88) | 0.5983 |
| aPL antibodies | 1.48 (0.71, 3.10) | 0.2985 |
| APS | 1.93 (0.85, 4.36) | 0.1159 |
| SLEDAI | 1.01 (0.87, 1.18) | 0.8758 |
| SLEDAI score >4 | 1.31 (0.45, 3.78) | 0.6155 |
| Low C3 | 0.50 (0.15, 1.64) | 0.251 |
| Hormonal contraception | 0 (0-Inf) | 0.9976 |
| Steroids | 1.95 (0.46, 8.22) | 0.3614 |
| Immunosuppressive drugsa | 1.63 (0.75, 3.53) | 0.2153 |
| Biological therapyb | 1.69 (0.59, 4.87) | 0.3274 |
| HCQ, ng/ml | 1.00 (0.99, 1.00) | 0.6526 |
| HS-cTnT, ng/l | 1.01 (1.00, 1.02) | 0.0066 |
Analysis was performed on 442 patients.
Immunosuppressive drugs included azathioprine, methotrexate, ciclosporin, mycophenolate, cyclophosphamide, thalidomide, tacrolimus, lenalidomide or sulfasalazine.
Biological therapy included rituximab or belimumab.
APS: anti phospholipid syndrome; HR: hazard ratio; HS-cTnT: high sensitivity cardiac troponin T.
Univariate analysis of risk factors for cardiovascular events in SLE patients
| . | HR (95% CI) . | P . |
|---|---|---|
| Age (for 10-year aged) | 1.79 (1.37, 2.34) | <0.0001 |
| Female gender | 0.81 (0.25, 2.69) | 0.7336 |
| Smoker, current | 1.96 (0.91, 4.22) | 0.0859 |
| Diabetes | 1.20 (0.16, 8.85) | 0.8588 |
| Dyslipidaemia | 4.88 (2.44, 9.76) | <0.0001 |
| Hypertension | 2.89 (1.39, 6.01) | 0.0045 |
| BMI | 1.05 (0.99, 1.12) | 0.1277 |
| BMI >30 kg/m2 | 1.71 (0.65, 4.51) | 0.2745 |
| Duration of SLE disease | 1.06 (1.02, 1.10) | 0.0024 |
| Lupus nephritis | 0.68 (0.16, 2.88) | 0.5983 |
| aPL antibodies | 1.48 (0.71, 3.10) | 0.2985 |
| APS | 1.93 (0.85, 4.36) | 0.1159 |
| SLEDAI | 1.01 (0.87, 1.18) | 0.8758 |
| SLEDAI score >4 | 1.31 (0.45, 3.78) | 0.6155 |
| Low C3 | 0.50 (0.15, 1.64) | 0.251 |
| Hormonal contraception | 0 (0-Inf) | 0.9976 |
| Steroids | 1.95 (0.46, 8.22) | 0.3614 |
| Immunosuppressive drugsa | 1.63 (0.75, 3.53) | 0.2153 |
| Biological therapyb | 1.69 (0.59, 4.87) | 0.3274 |
| HCQ, ng/ml | 1.00 (0.99, 1.00) | 0.6526 |
| HS-cTnT, ng/l | 1.01 (1.00, 1.02) | 0.0066 |
| . | HR (95% CI) . | P . |
|---|---|---|
| Age (for 10-year aged) | 1.79 (1.37, 2.34) | <0.0001 |
| Female gender | 0.81 (0.25, 2.69) | 0.7336 |
| Smoker, current | 1.96 (0.91, 4.22) | 0.0859 |
| Diabetes | 1.20 (0.16, 8.85) | 0.8588 |
| Dyslipidaemia | 4.88 (2.44, 9.76) | <0.0001 |
| Hypertension | 2.89 (1.39, 6.01) | 0.0045 |
| BMI | 1.05 (0.99, 1.12) | 0.1277 |
| BMI >30 kg/m2 | 1.71 (0.65, 4.51) | 0.2745 |
| Duration of SLE disease | 1.06 (1.02, 1.10) | 0.0024 |
| Lupus nephritis | 0.68 (0.16, 2.88) | 0.5983 |
| aPL antibodies | 1.48 (0.71, 3.10) | 0.2985 |
| APS | 1.93 (0.85, 4.36) | 0.1159 |
| SLEDAI | 1.01 (0.87, 1.18) | 0.8758 |
| SLEDAI score >4 | 1.31 (0.45, 3.78) | 0.6155 |
| Low C3 | 0.50 (0.15, 1.64) | 0.251 |
| Hormonal contraception | 0 (0-Inf) | 0.9976 |
| Steroids | 1.95 (0.46, 8.22) | 0.3614 |
| Immunosuppressive drugsa | 1.63 (0.75, 3.53) | 0.2153 |
| Biological therapyb | 1.69 (0.59, 4.87) | 0.3274 |
| HCQ, ng/ml | 1.00 (0.99, 1.00) | 0.6526 |
| HS-cTnT, ng/l | 1.01 (1.00, 1.02) | 0.0066 |
Analysis was performed on 442 patients.
Immunosuppressive drugs included azathioprine, methotrexate, ciclosporin, mycophenolate, cyclophosphamide, thalidomide, tacrolimus, lenalidomide or sulfasalazine.
Biological therapy included rituximab or belimumab.
APS: anti phospholipid syndrome; HR: hazard ratio; HS-cTnT: high sensitivity cardiac troponin T.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
